| Literature DB >> 18831747 |
Johan van Griensven1, Ludwig De Naeyer, Jeanine Uwera, Anita Asiimwe, Claire Gazille, Tony Reid.
Abstract
BACKGROUND: Although a number of studies have shown good results in treating children with antiretroviral drugs (ARVs) in hospital settings, there is limited published information on results in pediatric programs that are nurse-centered and based in health centers, in particular on the psychosocial aspects of care.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18831747 PMCID: PMC2570363 DOI: 10.1186/1471-2431-8-39
Source DB: PubMed Journal: BMC Pediatr ISSN: 1471-2431 Impact factor: 2.125
Traditional and modified tasks for nurses and physicians within the HIV/ART care program
| Initial physical exam/staging | X | X | ||
| Ordering CD4 count | X | X | X | |
| Assessment of ART eligibility | X | X | ||
| FU of non-eligible patients | X | X | ||
| CTX refill | X | -b | ||
| Complex medical cases | X | X | ||
| Ordering lab tests | X | X | X | |
| Interpretation of lab tests | X | X | ||
| ART initiation and FU | ||||
| Non-complex cases | X | X | ||
| Complex casesa | X | X | ||
| ART refill | X | -b | ||
| Register keeping/reporting | X | -b | ||
| Filing of results/medical records | X | -b | ||
| Training/mentoring | X | |||
| Supervision | X | |||
a Complex cases included those with advanced HIV disease, severe/persistent opportunistic infections, severe ART side-effects, suspicion of ART failure, severe or recurrent non-adherence to ART.
b Activities taken over from the ARV nurse by other staff.
ART: antiretroviral therapy; FU: follow-up; CTX: cotrimoxazole; MD: medical doctor
Figure 1Flow diagram of the pediatric HIV program. ART: antiretroviral treatment; PMTCT: Prevention of Mother To Child Transmission; WHO: World Health Organization.
Figure 2Picture from the booklet used to explain HIV/AIDS to children. The booklet is used by caregivers and health center staff. This picture is used to explain "what actually is blood ?" to the child.
Characteristics of children started on antiretroviral treatment (n = 315)
| Age at starta | 7.2 (4.5 – 10.4) |
| < 3 yearsb | 38 (12%) |
| 3 – 4.9 yearsb | 51 (16%) |
| 5 – 14.9 yearsb | 226 (72%) |
| Sex (male/female)b | 157/158 (50/50%) |
| Clinical WHO-stageqb | |
| WHO stage I | 43 (13.7%) |
| WHO stage II | 145 (46.0%) |
| WHO stage III | 115 (36.5%) |
| WHO stage IV | 12 (3.8%) |
| Weight for age (Z-score) (n = 293)a | -1.9 (-3.0;-0.9) |
| Baseline CD4 count % (n = 282)a | 14 (9–18) |
| < 15%b | 158 (56.0%) |
| 15–25%b | 118 (41.8%) |
| > 25%b | 6 (2.1%) |
| Baseline absolute CD4 counts (n= 302)a | 345 (229–572) |
| Baseline hemoglobin (mg/dl)(n = 268)a | 11.0 (10.3–11.8) |
| ART regimenb | |
| d4T/3TC/NVP | 281 (89.2%) |
| d4T/3TC/EFV | 6 (1.9%) |
| AZT/3TC/NVP | 19 (6.0%) |
| AZT/3TC/EFV | 9 (2.9%) |
| Time on ART (years)c | 2.0 (1.2–2.6) |
| Total patient years of follow-up | 598 |
| On tablets (FDC) | 577 |
| On syrup | 21 |
| < 1 year vs. ≥ 1 yearb | 59 (19 %) vs 256 (81 %) |
a Values are expressed as median (interquartile range)
b Values are expressed as n (%)
c As of June 30/2007 (closing date of dataset)
WHO: world health organization; ART: antiretroviral treatment; d4T: stavudine; 3TC: lamivudine; NVP: nevirapine; EFV: efavirenz; AZT: zidovudine; FDC: fixed-dose combination
Figure 3Kaplan Meier curve depicting the probability of survival or retention into the antiretroviral treatment (ART) program (n = 315). Children that had died or were lost to follow-up were considered as non-retained into ART care.
Clinical, immunological and virological outcomes for children on antiretroviral treatment (n = 315)
| CD4 count | |||||
| | 16 | 30 | 32 | 33 | 35 |
| IQR | (12–19) | (23–35) | (26–34) | (28–36) | (28–40) |
| N | 84 | 59 | 48 | 39 | 7 |
| | 13 | 25 | 26 | 29 | 29 |
| IQR | (9–17) | (18–29) | (21–32) | (24–34) | (19–33) |
| N | 198 | 175 | 117 | 80 | 24 |
| | 297 | 550 | 624 | 704 | 616 |
| IQR | (181–405) | (337–747) | (459–840) | (562–866) | (492–865) |
| N | 217 | 183 | 120 | 80 | 24 |
| Hb (mg/dl)b | 11.0 | 12.1 | 12.6 | 12.9 | 13.7 |
| WAZa | -1.9 | -1.6 | -1.6 | -1.5 | -1.5 |
| IQR | (-3.0;-0.9) | (-2.6;-0.8) | (-2.6;-0.7) | (-2.5;-0.6) | (-2.7;-0.6) |
| Viral load | |||||
| (n = 174) | 18 (15–23) | 127 (73.0%) | 144 (82.8%) | 151 (86.8%) | |
a Values are expressed as median (interquartile Range (IQR));
b Values are expressed as median;
c Values are expressed as n (%)
abs: absolute CD4 count (in cells/μL); Hb: hemoglobine; WAZ: Weight-for-age Z-score; ART: antiretroviral treatment
Psychosocial aspects of the pediatric HIV program
| - organization of discussion/support groups, at health center and in community |
| - family-based approach to identify eligible children |
| - individual counseling (pre-ART) |
| - psychosocial issues addressed in follow-up care |
| - adapted counseling for children for disclosure and ART (child-adapted tool) |
| - designated days for children's clinics |
| - child support groups |
| - integrated care, including disclosure, with their caregivers |
| - discussion groups for health care staff |
| - training on psychosocial implications of HIV |
| - practical training by psychosocial team (check-lists,...) |
| - supervision and mentoring |
ART: antiretroviral treatment
HIV: human immunodeficiency virus